HC Wainwright & Co. Maintains Buy on argenx, Raises Price Target to $482
HC Wainwright & Co. analyst Douglas Tsao maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $480 to $482.
Earnings Scheduled For March 2, 2023
Companies Reporting Before The Bell
• argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
argenx Q4 EPS $(0.70) Beats $(3.03) Estimate, Sales $182.12M Beat $176.89M Estimate
argenx (NASDAQ: ARGX) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(3.03) by 76.9 percent. This is a 85.29 percent increase over losses of $(4.76) per share from the same period last year.
Piper Sandler Maintains Overweight on argenx, Raises Price Target to $475
Piper Sandler analyst Allison Bratzel maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $465 to $475.
Immunovant Could Potentially Be An M&A Target, Writes Analyst
Cantor Fitzgerald initiated coverage on Immunovant Inc (NASDAQ:IMVT) with an Overweight rating and a price target of $30. The company’s pipeline includes…
Expert Ratings for argenx
Within the last quarter, argenx (NASDAQ:ARGX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 108 stocks hit new 52-week highs.
Argenx Enters Into Agreement To Acquire Priority Review Voucher For $102M
argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an agreement to acquire a U.S. Food and Drug
Argenx Announces U.S. FDA Acceptance Of Biologics License Application For Subcutaneous Efgartigimod In Generalized Myasthenia Gravis With Priority Review; PDUFA Date Is March 20, 2023
- Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023
- Submission based on positive results from the Phase 3 bridging study demonstrating noninferior total IgG reduction at day
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell
• Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.